Redeye states that the company has demonstrated excellent cost control during the first quarter of 2...
Redeye gives an updated view on Gapwaves after its Q1'23 report.
Redeye comments on Medivir’s first quarter report of 2023.
Redeye provides an update in relation to Enzymatica’s Q1 2023 report.
Redeye makes minor estimate revisions and updates its fair value range following Alelion’s Q1 report...
Redeye will likely leave its Base Case and forecasts roughly unchanged following Vertiseit’s Q1 repo...
Maven Wireless publicerade den 27 april 2023 bolagets delårsrapport för det första kvartalet 2023 oc...
Blick Global publicerade den 27 april år 2023 bolagets delårsrapport för det första kvartalet 2023.
Sales and EBITA way above expectations (+26% and +120%) Organic growth of +31%, EBITA margin of 6.
Brittiska förvärvet fortsätter kompensera för vikande nordisk marknad.
Postponed sales from Q4'22 boost Q1 sales Q1 was the strongest ever quarter in APAC, 55% growth Shar...
Stark trend i ARR-tillväxt bruten Omsättningen i kvartalet uppgick till 36,2 mkr vilket motsvarar en...
Q1-rapporten signalerar en bra start på året trots ett osäkert marknadsläge Nettoomsättningen ökade ...
3% sales miss, but better underlying profits than expected '23e-'25e EBIT down 12-5% on lower sales ...
Dovre’s Q1 profitability came in above our estimates despite some softness in top line attributable ...
IAR Systems’ Q1 results were soft and missed our adj.
Finnair’s Q1 results topped estimates as high unit yields drove passenger revenue.
SRV's net sales in Q1 declined clearly to EUR 138.3m, below our and consensus estimates (EUR 147.
Scanfil’s Q1 figures beat estimates even if expectations were already high.
Q1: EBIT SEK 149m vs. ABGSCe of SEK 90m Chinese NBSK import price down ~20% YTD Fair value range: SE...
